RxDoctor Payments Data

Mohamed Nassar

Internal Medicine · Redlands, CANPI 1346545043

Payments from drug & device makers

$333in general payments, 2019–2025

Across 18 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$103
  • Novo Nordisk$57
  • AbbVie$42
  • Novartis$35
  • AstraZeneca$26
  • Abbott$24
  • plus $45 from 2 others

What the payments were for

  • Food & beverage$333100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer6$103
Novo Nordisk3$57
AbbVie2$42
Novartis2$35
AstraZeneca1$26
Abbott2$24
Merck1$24
Lilly USA, LLC1$21

How this compares

$333 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$89,920
Medicare patients
257
Services billed
999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide126$181,707
EliquisApixaban231$158,301
TrulicityDulaglutide39$60,721
JanuviaSitagliptin Phosphate47$55,718
ProliaDenosumab27$44,534
RybelsusSemaglutide36$43,545
KerendiaFinerenone24$41,774
JardianceEmpagliflozin26$38,858
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$36,481
MounjaroTirzepatide16$29,698
XareltoRivaroxaban47$29,380
MyrbetriqMirabegron39$27,588
FarxigaDapagliflozin Propanediol19$23,685
Breo ElliptaFluticasone/Vilanterol13$9,714
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$9,299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$57$225,252162 claims
Lilly USA, LLCTrulicity, Mounjaro$21$90,41855 claims
MerckJanuvia, Belsomra, Dulera$24$69,97871 claims
BayerKerendia$103$41,77424 claims
AstraZenecaFarxiga, Brilinta$26$28,78231 claims
AbbVieSynthroid$42$4,24053 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Redlands

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →